EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Microfluidic Framework for Neuroprotective Compound Triage Across Ischemia and Neurodegeneration

Julia Anchimowicz iD, Slawomir Jakiela iD

Molecules · 2026

DOI: 10.3390/molecules31101622 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2026. Verfasst von Julia Anchimowicz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics and Biophysics, Institute of Biology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland. Hauptthemen laut MEDLINE: Neuroprotective Agents, Microfluidics, Neurodegenerative Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microfluidic systems are increasingly used in neuroprotection research, but their clearest value may be to show why candidate compounds fail before costly downstream models. This critical framework review examines CNS-relevant microfluidic studies through a within-program triage logic linking chemistry-aware prescreening, blood-brain barrier/neurovascular unit (BBB/NVU) filtering, and timed validation in neuronal ischemia/reperfusion models, and treats non-CNS organ-on-a-chip and analytical microfluidic studies as engineering analogies only. The available evidence most strongly supports BBB/NVU chips as exposure- and safety-aware filters and compartmentalized neuronal oxygen-glucose deprivation platforms as timing-sensitive validation tools; droplet microfluidics contributes mainly upstream through dense dose mapping, aggregation assays and counterscreens for assay interference. A compound-centered reading also suggests that apparent activity often fails for distinct reasons, including timing mismatch, poor solubility, surface adsorption, optical artifact, inadequate multicellular context, or loss of efficacy under transport-aware testing. Taken together, the literature supports a cautious, within-program triage logic in which microfluidics is used not as a universal disease model, but as an operational framework for exposing transport, barrier, timing and assay liabilities early in neuroprotective discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroprotective AgentsMicrofluidicsNeurodegenerative DiseasesHumansAnimalsBlood-Brain BarrierMicrophysiological SystemsLab-On-A-Chip Devices

Stichwörter der Autor:innen

blood-brain barrierischemia-reperfusionmicrofluidicsmitochondrianervous-system organ-on-a-chipneurodegenerationneurovascular unitorgan-on-a-chipphenotypic screeningstroke

Substanzen

Neuroprotective Agents

Autor:innen und Institutionen

  • Department of Physics and Biophysics, Institute of Biology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland.

ORCID-Profile: Julia Anchimowicz, Slawomir Jakiela

Förderung

  • National Science Centre
  • National Science Centre, Poland

Zitieren

APA

Anchimowicz, J., & Jakiela, S. (2026). A Microfluidic Framework for Neuroprotective Compound Triage Across Ischemia and Neurodegeneration. Molecules. https://doi.org/10.3390/molecules31101622

Vancouver

Anchimowicz J, Jakiela S. A Microfluidic Framework for Neuroprotective Compound Triage Across Ischemia and Neurodegeneration. Molecules. 2026. doi:10.3390/molecules31101622

BibTeX
@article{Anchimowicz2026,
  author = {Anchimowicz, Julia and Jakiela, Slawomir},
  title = {A Microfluidic Framework for Neuroprotective Compound Triage Across Ischemia and Neurodegeneration},
  journal = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31101622}
}
Kostenlos starten →